Trajan Group Holdings Valuation
Is TRJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TRJ?
Other financial metrics that can be useful for relative valuation.
| What is TRJ's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | AU$281.36m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 29.4x |
| PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does TRJ's PE Ratio compare to its peers?
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 21.3x | ||
CTE Cryosite | 30.2x | n/a | AU$38.1m |
EZZ EZZ Life Science Holdings | 7x | n/a | AU$17.5m |
PBP Probiotec | 13.3x | 15.6% | AU$194.4m |
CUV Clinuvel Pharmaceuticals | 34.9x | 23.2% | AU$928.4m |
TRJ Trajan Group Holdings | 59.4x | 29.9% | AU$281.4m |
Price to Earnings Ratio vs Industry
How does TRJ's PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price to Earnings Ratio vs Fair Ratio
What is TRJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 59.4x |
| Fair PE Ratio | 30.3x |
Price-To-Earnings vs Fair Ratio: TRJ is expensive based on its Price-To-Earnings Ratio (59.4x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).
Share Price vs Fair Value
What is the Fair Price of TRJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?